Zanubrutinib Oral Capsule

Phase 2

TThe Lymphoma Academic Research Organisation

Zanubrutinib Oral Capsule is one of 3 therapeutic programs targeting Lymphoma, Mantle-Cell. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lymphoma, Mantle-CellRecruiting

Lymphoma, Mantle-CellPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Lymphoma, Mantle-Cell

#DrugCompanyPhaseTrials

Gazyva

Roche

Phase 2

1 2

COLUMVI

Roche

Phase 2

1 3

Zanubrutinib Oral Capsule

TThe Lymphoma Academic Research Organisation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Lymphoma, Mantle-Cell

NCT06558604

Clinical

Trials by Indication[1]

Lymphoma, Mantle-Cell1 trial

A Phase II, Multicenter, Open-label Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT06558604·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zanubrutinib Oral Capsule. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Zanubrutinib Oral Capsule. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The Lymphoma Academic Research Organisation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TThe Lymphoma Academic Research Organisation

Zanubrutinib Oral Capsule

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Lymphoma, Mantle-Cell1 trial

References

Drug Info

Quick Facts

Related News